Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3876
PUT
Southern Company
SO
$106B
| $436K | ﹤0.01% |
5,000
| – | – |
|
3877
Telkom Indonesia
TLK
$14.4B
| $436K | ﹤0.01% |
20,701
-9,532
| -32% | -$195K |
|
3878
Inspired Entertainment
INSE
$163M
| $436K | ﹤0.01% |
46,535
+3,155
| +7% | +$26.6K |
|
3879
Gencor Industries
GENC
$265M
| $435K | ﹤0.01% |
33,587
+1,610
| +5% | +$21.6K |
|
|
CMRC
3880
Commerce.com Inc Series 1
CMRC
$179M
| $433K | ﹤0.01% |
105,082
+10,915
| +12% | +$50.3K |
|
3881
Riverview Bancorp
RVSB
$106M
| $433K | ﹤0.01% |
86,231
+3,325
| +4% | +$17.4K |
|
3882
Aclaris Therapeutics
ACRS
$860M
| $432K | ﹤0.01% |
143,414
+19,989
| +16% | +$50.5K |
|
3883
Unusual Machines
UMAC
$1.35B
| $429K | ﹤0.01% |
33,650
+26,599
| +377% | +$312K |
|
|
CIO
3884
DELISTED
City Office REIT
CIO
| $426K | ﹤0.01% |
60,887
+5,828
| +11% | +$40.3K |
|
3885
First National Corp
FXNC
$288M
| $425K | ﹤0.01% |
16,825
+2,791
| +20% | +$66.3K |
|
|
LOVE
3886
LoveSac
LOVE
$253M
| $421K | ﹤0.01% |
28,576
+1,999
| +8% | +$28.3K |
|
3887
DiaMedica Therapeutics
DMAC
$369M
| $421K | ﹤0.01% |
52,911
+7,471
| +16% | +$55.9K |
|
3888
Boston Omaha
BOC
$436M
| $420K | ﹤0.01% |
33,975
+3,279
| +11% | +$42.7K |
|
3889
CALL
ING
ING
$102B
| $420K | ﹤0.01% |
+15,000
| New | +$387K |
|
3890
Distribution Solutions Group
DSGR
$1.61B
| $420K | ﹤0.01% |
15,327
+1,201
| +9% | +$33.8K |
|
3891
C4 Therapeutics
CCCC
$480M
| $419K | ﹤0.01% |
219,204
+176,142
| +409% | +$417K |
|
|
WBTN
3892
WEBTOON Entertainment Inc
WBTN
$1.17B
| $418K | ﹤0.01% |
32,073
+6,804
| +27% | +$104K |
|
3893
AB InBev
BUD
$156B
| $417K | ﹤0.01% |
6,518
-161,317
| -96% | -$10M |
|
3894
RCI Hospitality Holdings
RICK
$214M
| $416K | ﹤0.01% |
17,462
+1,188
| +7% | +$30.4K |
|
|
JCAP
3895
Jefferson Capital
JCAP
$1.3B
| $416K | ﹤0.01% |
18,624
-1,595
| -8% | -$32.2K |
|
|
WOW
3896
DELISTED
WideOpenWest
WOW
| $415K | ﹤0.01% |
79,796
+8,606
| +12% | +$44.4K |
|
3897
CALL
Constellation Brands
STZ
$22.9B
| $414K | ﹤0.01% |
+3,000
| New | +$412K |
|
|
HUT
3898
PUT
Hut 8
HUT
$11.2B
| $413K | ﹤0.01% |
9,000
-414,700
| -98% | -$18.3M |
|
3899
CALL
Infosys
INFY
$49.7B
| $413K | ﹤0.01% |
23,200
-2,669,500
| -99% | -$46.2M |
|
3900
Invesco DB Commodity Index Tracking Fund
DBC
$1.73B
| $413K | ﹤0.01% |
18,487
+1,896
| +11% | +$43.1K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.